Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background & Aims: Naturally occurring variation in Membrane-bound O-acyltransferase domain-containing 7 (MBOAT7), an enzyme involved in phospholipid acyl-chain remodeling, has been associated with steatosis and hepatic disorders. We examined the relationship between hepatic MBOAT7 down-regulation and fat accumulation. Methods: Hepatic MBOAT7 expression was surveyed in 119 obese individuals and in experimental models. MBOAT7 was acutely silenced by antisense oligonucleotides in C57Bl/6 mice, and by CRISPR/Cas9 in HepG2. Results: In obese individuals, hepatic MBOAT7 mRNA decreased from normal liver to steatohepatitis, independently of diabetes, inflammation and MBOAT7 genotype. Mboat7 levels were reduced in murine models of fatty liver, and by hyperinsulinemia. In wild-type mice, Mboat7 was down-regulated by refeeding and insulin, concomitantly with insulin signaling activation. Acute hepatic Mboat7 silencing promoted hepatic steatosis in vivo and enhanced expression of fatty acid transporter Fatp1. MBOAT7-/- HepG2 showed altered phospholipids remodeling consistent with decreased enzymatic activity, increased triglyceride accumulation, enhanced lipogenesis and FATP1 expression, while FATP1 deletion rescued the phenotype. Conclusions: These results suggest that MBOAT7 down-regulation by hyperinsulinemia contributes to hepatic fat accumulation, impairing phospholipids remodeling and up-regulating FATP1.Funding Statement: LV was supported by MyFirst Grant AIRC n.16888, Ricerca Finalizzata Ministero della Salute RF-2016-02364358, Ricerca corrente Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, LV and AG. received funding from the European Union (EU) Programme Horizon 2020 (under grant agreement No. 777377) for the project LITMUS-“ Liver Investigation: Testing Marker Utility in Steatohepatitis”. MM was supported by Fondazione Italiana per lo Studio del Fegato (AISF) ‘Prof. Mario Coppo’ fellowship. AG received funding from the European Union (EU) Programme Horizon 2020 under grant agreement no. 634413 for the project EPoS-“Elucidating Pathways of Steatohepatitis”. Declaration of Interests: The authors declare no conflict of interest relevant to the present manuscript.Ethics Approval Statement: Informed written consent was obtained from each patient and the study protocol was approved by the Ethical Committee of the Fondazione IRCCS Ca’ Granda of Milan and conforms to the ethical guidelines of the 1975 Declaration of Helsinki. We received an approval from an Animal Use Committee for the animal work from the University of Milan and the Italian Ministry of Health Review Boards, in the context of the protocol 8/14, as indicated in the material and methods section in the manuscript. The authorization number of this protocol is 295/2012–A, received on 12/20/2012.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Self-citationNonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581 · cited 5×
“Nash Nonalcoholic fatty liver disease Steatohepatitis Phospholipid Phosphatidylinositol lipoprotein B; BMI, Body Mass Index; CDP, Cytidine-Diphosphate; CI, Confidence Interval; CL, Cardiolipin; CPT1, Carnitine paced Short Palindromic Repeats; CXCL10, C-X-C Motif Chemokine 10; DAG, Diacylglycerol; FABP1, Fatty Acid-Bin…”
BackgroundInfluentialNakae, J., Kitamura, T., Silver, D. L., & Accili, D. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200112876 · Cited by 652
Buch, S., Stickel, F., Trépo, E., Way, M., Herrmann, A., Nischalke, H. D., Brosch, M., Rosendahl, J., Berg, T., Ridinger, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3417 · Cited by 565
Dongiovanni, P., Petta, S., Maglio, C., Fracanzani, A. L., Pipitone, R., Mozzi, E., Motta, B. M., Kaminska, D., Rametta, R., Grimaudo, S., et al. (2015) · Hepatology · doi:10.1002/hep.27490 · Cited by 533
Self-citationHashidate-Yoshida, T., Harayama, T., Hishikawa, D., Morimoto, R., Hamano, F., Tokuoka, S. M., Eto, M., Tamura-Nakano, M., Yanobu-Takanashi, R., Mukumoto, Y., et al. (2015) · eLife · doi:10.7554/elife.06328 · Cited by 270
PNPLA3 I148M polymorphism and progressive liver disease
Dongiovanni, P. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i41.6969 · Cited by 252 · cited 2×
“All patients were genotyped for PNPLA3 rs738409 (p.I148M) and MBOAT7 rs641738 by TaqMan 50-nuclease assays (Life Technologies, Carlsbad, CA) [11,22].”
Self-citation
Cited by
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests
Masoodi, M., Gastaldelli, A., Hyötyläinen, T., Arretxe, E., Alonso, C., Gaggini, M., Brosnan, J., Anstee, Q. M., Millet, O., Ortiz, P., et al. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00502-9 · Cited by 451
Self-citationThe Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease
Fujii, H., Kawada, N., & Japan Study Group of NAFLD (JSG-NAFLD) (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113863 · Cited by 299
Jamialahmadi, O., Mancina, R. M., Ciociola, E., Tavaglione, F., Luukkonen, P. K., Baselli, G., Malvestiti, F., Thuillier, D., Raverdy, V., Männistö, V., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.12.023 · Cited by 148
Self-citationCherubini, A., Ostadreza, M., Jamialahmadi, O., Pelusi, S., Rrapaj, E., Casirati, E., Passignani, G., Norouziesfahani, M., Sinopoli, E., Baselli, G., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02553-8 · Cited by 136
Self-citationHepatic glucose metabolism in the steatotic liver
Scoditti, E., Sabatini, S., Carli, F., & Gastaldelli, A. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00888-8 · Cited by 134
“Meroni and colleagues 140 found that the MBOAT7 mRNA and protein downregulation in hepatocytes was promoted by hyperinsulinae-mia and that the downregulation of MBOAT7 in the liver of patients with MASLD was associated with hepatic inflammation, Hep-IR and glucose intolerance independently of…”
Self-citation
Metadata
- Authors
- Meroni, M., Dongiovanni, P., Longo, M., Carli, F., Baselli, G., Rametta, R., Pelusi, S., Badiali, S., Maggioni, M., Gaggini, M., Fracanzani, A. L., Romeo, S., Gatti, S., Davidson, N. O., Gastaldelli, A., & Valenti, L.
- Venue
- EBioMedicine
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 52
- Pages
- 102658
- ISSN
- 2352-3964 (ISSN-L)
- OpenAlex
- W3006029231
- Cited by
- 90
- References
- 7
- FWCI
- 7.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes. https://app.cochat.ai/papers/10.1016/j.ebiom.2020.102658
- The paper
- Meroni, M., Dongiovanni, P., Longo, M., Carli, F., Baselli, G., Rametta, R., Pelusi, S., Badiali, S., Maggioni, M., Gaggini, M., Fracanzani, A. L., Romeo, S., Gatti, S., Davidson, N. O., Gastaldelli, A., & Valenti, L. (2020). Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes. EBioMedicine. https://doi.org/10.1016/j.ebiom.2020.102658
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.